Credit Suisse’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Credit Suisse’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-44,800	Closed	-$1.23M	–	3441
2022 Q4	$1.23M	Sell	44,800 -8,172	-15%	-$217K	﹤0.01%	2197
2022 Q3	$1.27M	Sell	52,972 -7,731	-13%	-$200K	﹤0.01%	2150
2022 Q2	$1.6M	Sell	60,703 -694	-1%	-$18.3K	﹤0.01%	2060
2022 Q1	$1.63M	Sell	61,397 -657	-1%	-$17K	﹤0.01%	2219
2021 Q4	$1.68M	Sell	62,054 -62	-0.1%	-$1.63K	﹤0.01%	2914
2021 Q3	$1.59M	Buy	62,116 +2,354	+4%	+$61.8K	﹤0.01%	2991
2021 Q2	$1.55M	Buy	59,762 +9,762	+20%	+$252K	﹤0.01%	3051
2021 Q1	$1.28M	Hold	50,000	–	–	﹤0.01%	3148
2020 Q4	$1.29M	Sell	50,000 -426	-0.8%	-$10.6K	﹤0.01%	3143
2020 Q3	$1.21M	Buy	+50,426	New	+$1.21M	﹤0.01%	2790

Other funds holding FTXH

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

WFA

WMG Financial Advisors Knoxville, Tennessee $265M AUM 26.03% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

Nilsine Partners Greenwood Village, Colorado $1.45B AUM 47.06% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

KNW

Kesler Norman & Wride Ogden, Utah $631M AUM 27.63% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return

PPWM

Paragon Private Wealth Management Lexington, Kentucky $320M AUM 23.48% 1-Year Est. Return

Credit Suisse's FTXH Position: Q1 2023 in Review

Credit Suisse sold out of First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q1 2023, closing a stake of 44,800 shares — an estimated $1.23M sold.

Credit Suisse first reported a position in FTXH in Q3 2020 and held it in 10 quarters. The position peaked at $1.68M in Q4 2021. 31 funds tracked by Wall St. Rank hold FTXH as of Q1 2023.

Credit Suisse reported no remaining First Trust Nasdaq Pharmaceuticals ETF position as of Q1 2023 after selling out during the quarter.
Credit Suisse sold 44,800 First Trust Nasdaq Pharmaceuticals ETF shares in Q1 2023, an estimated $1.23M.
Credit Suisse first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q3 2020 and held it in 10 quarters.
Credit Suisse's First Trust Nasdaq Pharmaceuticals ETF position peaked at $1.68M in Q4 2021.
31 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.